Masimo’s COVID-19 Response Efforts Highlighted at California Life Sciences Association’s Pantheon 2020

Rhea-AI Summary

Masimo (NASDAQ: MASI) was recognized as one of seven innovators at California Life Sciences Association's Pantheon 2020 for its role in addressing COVID-19 challenges. The company's Masimo SafetyNet platform supports remote patient monitoring, enabling clinicians to track patients' health metrics from home, thus alleviating hospital strain. Mike Guerra from CLSA praised Masimo's adaptability during the pandemic. CEO Joe Kiani acknowledged the frontline healthcare workers' contributions and highlighted the impact of their technology in improving patient outcomes.

Positive

• Masimo SafetyNet platform enhances remote patient monitoring, crucial during COVID-19.
• Recognized at Pantheon 2020, highlighting innovation in life sciences.
• Ability to rapidly deploy and scale Masimo SafetyNet without additional infrastructure.

Negative

• None.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) is proud to have been one of seven California innovators featured at Pantheon 2020, the annual event at which the California Life Sciences Association (CLSA) brings together industry leaders in the life sciences to recognize outstanding achievements. Held virtually this year, Pantheon 2020, which took place last Thursday, was anchored by a series of videos and panels highlighting stories of scientific innovation, collaboration, and progress focused on celebrating efforts to combat COVID-19. Masimo, the only patient monitoring company featured, was also one of the three companies highlighted at CLSA’s “Celebrating California Innovation” event, and at a session dedicated to exploring how Masimo SafetyNet™ is playing a key role in Masimo’s efforts to help clinicians and hospitals around the world fight the pandemic.

Mike Guerra, President and CEO of CLSA, commented, “Masimo is an exemplary illustration of the resiliency and flexibility shown by life sciences companies when California and the world were faced with a global pandemic. The adaptability of their remote patient monitoring technology has saved lives and allowed patients to recover from their homes, thereby freeing up critically needed hospital beds.”

In early 2020, harnessing its expertise in noninvasive patient monitoring, automation, and telehealth solutions, Masimo developed Masimo SafetyNet, a secure, home-based patient management platform combining hospital-grade tetherless pulse oximetry, continuous temperature measurement, and a remote data capture and surveillance platform. Designed to help hospitals accommodate surges in COVID-19 patient volume and help lower-acuity patients recover at home and in other alternate care spaces, Masimo SafetyNet allows clinicians to keep an eye on their patients’ physiological status—including oxygen saturation, respiration rate, pulse rate, and temperature—from afar, at all times. Already in use at numerous institutions in the U.S. and beyond, Masimo SafetyNet can be rapidly deployed and easily scaled as needed, without additional hardware or network infrastructure, helping caregivers provide the best possible care as the pandemic worsens.

In his speech at Pantheon 2020, Joe Kiani, Founder and CEO of Masimo, said, “I want to thank CLSA for highlighting our work in helping with the global pandemic. I also want to take this time to say we’re humbled by this, because in fact, the real heroes are the people on the front lines using the tools we create to help patients, especially those with COVID-19. We’ve never seen anything like COVID-19, but as a member of CLSA, we’re proud to have used life sciences technology, mathematics, and engineering to do the work that we have; together we are making a difference in so many people’s lives.”

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET^® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.¹ Masimo SET^® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,² improve CCHD screening in newborns,³ and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs^4-7 Masimo SET^® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,⁸ and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S. News and World Report Best Hospitals Honor Roll.⁹ Masimo continues to refine SET^® and in 2018, announced that SpO₂ accuracy on RD SET^® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO₂ values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow^® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb^®), oxygen content (SpOC™), carboxyhemoglobin (SpCO^®), methemoglobin (SpMet^®), Pleth Variability Index (PVi^®), RPVi™ (rainbow^® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root^® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine^® Brain Function Monitoring, O3^® Regional Oximetry, and ISA™ Capnography with NomoLine^® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters^® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7^® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat^® Rx, and devices available for use both in the hospital and at home, such as Rad-97^®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris Gateway^®, Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView: 60™, and Masimo SafetyNet™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

1. Published clinical studies on pulse oximetry and the benefits of Masimo SET^® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
2. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO₂ Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
3. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
4. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
5. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
6. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
7. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
8. Estimate: Masimo data on file.
9. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo SafetyNet^™. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo SafetyNet, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.